Ureaplasma urealyticum is a very small type of bacterium that lives in the urogenital tract of many adults, often without causing any symptoms at all. It belongs to the Mycoplasma family, a group of bacteria that lack a cell wall, which makes them naturally resistant to common antibiotics like penicillin and amoxicillin that work by attacking bacterial cell walls. Whether U. urealyticum acts as a harmless resident or a genuine pathogen remains one of the more debated questions in microbiology.
Commensal or Pathogen?
U. urealyticum is extremely common. In a study of over 1,100 women of reproductive age, Ureaplasma species were detected in about 24% of them. Among the women who had zero symptoms, 14% still tested positive. Of the 89 women specifically positive for U. urealyticum (as opposed to its close relative U. parvum), about 30% were completely asymptomatic while 70% reported at least one symptom like itching, burning, discharge, or pelvic discomfort.
This split is what makes U. urealyticum tricky. Some researchers classify it as a commensal organism, meaning it simply lives in your body without causing harm. Others point to its strong associations with urethritis in men, pelvic inflammation in women, and complications during pregnancy. The CDC notes that the majority of men with Ureaplasma infections do not have overt disease unless a high organism load is present, suggesting that the amount of bacteria matters more than simply whether it’s there.
How It Spreads
Sexual contact is the primary transmission route. A pregnant person can also pass U. urealyticum to their baby during delivery as the infant moves through the birth canal, or less commonly through infection that ascends into the uterus during pregnancy or reaches the fetus through the umbilical cord’s blood supply.
Symptoms in Women
When U. urealyticum does cause problems in women, the most common complaints are burning or pain during urination, pelvic pain, urethral irritation, and unusual vaginal discharge. It can also cause endometritis, an inflammation of the uterine lining that may lead to abnormal vaginal bleeding, fever, and additional discharge. In rare cases, it may contribute to kidney stone formation.
Many women first learn about U. urealyticum during a fertility evaluation. It has been associated with unexplained infertility, though pinning down exactly how much it contributes is difficult given how often it’s found in healthy women too.
Symptoms in Men
In men, U. urealyticum is most closely linked to non-gonococcal urethritis, an inflammation of the urethra not caused by gonorrhea. Symptoms typically include a burning sensation during urination and sometimes a clear or thin discharge. However, the CDC describes the evidence connecting Ureaplasma species to urethritis as inconsistent, and most men carrying the organism have no noticeable symptoms unless bacterial levels are high.
Pregnancy Complications
The strongest evidence for U. urealyticum as a genuine pathogen comes from pregnancy research. It has been causally linked to early pregnancy loss, stillbirth, and preterm birth. Ureaplasma species are the most common organisms found in amniotic fluid from women experiencing preterm labor with intact membranes, premature rupture of membranes, or short cervix with microbial invasion. Depending on the specific scenario, Ureaplasma is the sole microbe cultured from 6% to 22% of infected amniotic fluid samples.
The infection triggers a significant inflammatory response. In cases of premature membrane rupture, Ureaplasma presence is associated with elevated white blood cells and inflammatory markers in both the amniotic fluid and the baby’s cord blood. Around 78% of placentas from infants colonized with Ureaplasma showed signs of chorioamnionitis (inflammation of the placental membranes), compared to 36% of placentas from uninfected infants.
For preterm infants, Ureaplasma colonization of the respiratory tract raises the risk of bronchopulmonary dysplasia, a chronic lung condition. A meta-analysis covering roughly 3,000 preterm infants found a significant association between Ureaplasma respiratory colonization and this lung disease. Lung tissue from infected preterm infants shows moderate to severe scarring and disordered development compared to uninfected infants of the same gestational age.
Effects on Fertility and IVF
Despite widespread concern, recent evidence suggests U. urealyticum’s impact on male fertility may be more limited than previously thought. A study comparing semen parameters between infected and uninfected men found no significant differences in sperm concentration, motility, or morphology. Progressive motility was marginally higher in the infected group (about 42% versus 39%), though this difference was not statistically meaningful. The study also found that male U. urealyticum infection had minimal impact on IVF outcomes, including embryo quality, pregnancy rates, and newborn health.
In women, the picture is less clear. U. urealyticum has been linked to tubal inflammation and endometritis, both of which can impair fertility, but large controlled studies isolating its specific contribution are limited.
How It’s Diagnosed
The two main testing methods are bacterial culture and PCR (a DNA-based test). PCR is faster and can identify the specific species, distinguishing U. urealyticum from U. parvum. When measured against culture results, PCR picks up about 89% to 96% of true positives depending on sample type, with very few false positives. PCR also has a practical advantage: about 5% of culture samples get overgrown by other bacteria and become unreadable, while PCR can still analyze those specimens. Detection accuracy improves with higher bacterial loads, which aligns with the clinical observation that higher organism counts tend to matter more than simple presence.
It’s worth noting that routine screening is not currently recommended. The CDC advises against testing for U. urealyticum, U. parvum, or Mycoplasma hominis as part of standard STI workups. Testing is generally reserved for people with persistent urethritis that doesn’t respond to initial treatment, recurrent pregnancy complications, or unexplained fertility issues.
Treatment and Antibiotic Resistance
Because U. urealyticum lacks a cell wall, antibiotics that target cell walls (penicillins, cephalosporins) are useless against it. Treatment relies on antibiotics from the tetracycline, macrolide, or fluoroquinolone families. Tetracycline-class antibiotics remain the most reliable option, with only about 8% of Ureaplasma species showing resistance globally. Macrolide resistance sits around 19%. Fluoroquinolone resistance is the most concerning at 66%, making that drug class the least dependable choice.
These resistance patterns are a global average and vary by region, so local resistance data can influence which antibiotic a clinician selects. Treatment typically involves a course lasting one to two weeks, and sexual partners generally need to be treated simultaneously to prevent reinfection.